A literature review of the epidemiology and treatment of acute gout

Clinical Therapeutics

Volumn 25, Issue 6, 2003, Pages 1593-1617

  Kim, Karissa Y ^a   Schumacher, H Ralph ^b,c   Hunsche, Elke ^d   Wertheimer, Albert I ^a   Kong, Sheldon X ^d  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Burden of illness; Drug therapy; Epidemiology; Gout; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; CYANOCOBALAMIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; CYTOTOXIC AGENT; ETHAMBUTOL; ETODOLAC; ETORICOXIB; FLURBIPROFEN; INDOMETACIN; KETOROLAC TROMETAMOL; LEVODOPA; LOOP DIURETIC AGENT; MECLOFENAMIC ACID; MISOPROSTOL; NAPROXEN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROBENECID; PROTON PUMP INHIBITOR; PYRAZINAMIDE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; URATE; URIC ACID;

ATROPHY; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; CYTOPENIA; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; ECONOMIC ASPECT; ENDOCRINE DISEASE; ENVIRONMENTAL FACTOR; ETHNOLOGY; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GOUT; HEADACHE; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERURICEMIA; HYPOKALEMIA; HYPOPIGMENTATION; INFECTION; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LIVER NECROSIS; MATHEMATICAL MODEL; MEDICAL LITERATURE; MYOPATHY; NAUSEA; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; OSTEOPOROSIS; PARALYSIS; PROPHYLAXIS; PSYCHOSIS; PUBLICATION; RASH; REVIEW; RISK FACTOR; SOMNOLENCE; TISSUE NECROSIS; TREATMENT INDICATION; UNITED STATES; URTICARIA; VERTIGO; VOMITING;

EID: 0038391240     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80158-3     Document Type: Review

References (125)

1. Star VL, Hochberg MC. Prevention and management of gout. Drugs. 1993;45:212-222.
2. Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am. 1990;16:539-550.
3. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician. 1999;59:925-934.
4. van Doornum S, Ryan PF. Clinical manifestations of gout and their management. Med J Aust. 2000;172:493-497.
5. Scott JT. Gout. Ann Rheum Dis. 1983;42(Suppl 1):16-18.
6. Hawkins DW, Rahn DW. Gout and hyperuricemia. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 4th ed. Stamford, Conn: Appelton & Lange; 1999:1460-1465.
7. Snaith ML. ABC of rheumatology. Gout, hyperuricaemia, and crystal arthritis. BMJ. 1995;310:521-524.
8. McGill NW. Gout and other crystal arthropathies. Med J Aust. 1997;166:33-38.
9. Agudelo CA, Wise CM. Gout: Diagnosis, pathogenesis, and clinical manifestations. Curr Opin Rheumatol. 2001;13:234-239.
10. Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician. 1999;59:1799-1806.
11. Dieppe PA. Investigation and management of gout in the young and the elderly. Ann Rheum Dis. 1991;50:263-266.
12. Pascual E. Gout update: From lab to the clinic and back. Curr Opin Rheumatol. 2000;12:213-218.
13. Scott JT. Gout: The last 50 years. J R Soc Med. 1996;89:634-637.
14. Shadick NA, Kim R, Weiss S, et al. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: The normative aging study. J Rheumatol. 2000;27:1708-1712.
15. Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43:103-108.
16. Brand FN, McGee DL, Kannel WB, et al. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol. 1985;121:11-18.
17. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: The Framingham Study. J Clin Epidemiol. 1988;41:237-242.
18. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-Up Study. Am J Epidemiol. 1995;141:637-644.
19. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol. 2002;14:281-286.
20. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266:3008-3011.
21. Davidson MB. Clinical implications of insulin resistance syndromes. Am J Med. 1995;99:420-426.
22. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis. 1998;57:509-510.
23. Puig JG, Mateos FA, Sancho T, et al. Gout: New questions for an ancient disease. Adv Exp Med Biol. 1998;431:1-5.
24. Chou P, Lin KC, Lin HY, Tsai ST. Gender differences in the relationships of serum uric acid with fasting serum insulin and plasma glucose in patients without diabetes. J Rheumatol. 2001;28:571-576.
25. Gelber AC, Klag MJ, Mead LA, et al. Gout and risk for subsequent coronary heart disease. The Meharry-Hopkins Study. Arch Intern Med. 1997;157:1436-1440.
26. Pascual E. Hyperuricemia and gout. Curr Opin Rheumatol. 1994;6:454-458.
27. Weinberger A. Gout, uric acid metabolism, and crystal-induced inflammation. Curr Opin Rheumatol. 1995;7:359-363.
28. Perkins P, Jones AC. Gout. Ann Rheum Dis. 1999;58:611-617.
29. Agarwal AK. Gout and pseudogout. Prim Care. 1993;20:839-855.
30. Garcia CO, Kutzbach AG, Espinoza LR. Characteristics of gouty arthritis in the Guatemalan population. Clin Rheumatol. 1997;16:45-50.
31. Prior IA, Welby TJ, Ostbye T, et al. Migration and gout: The Tokelau Island migrant study. BMJ. 1987;295:457-461.
32. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol. 2000;27:1045-1050.
33. Michet CJ Jr, Evans JM, Fleming KC, et al. Common rheumatologic diseases in elderly patients. Mayo Clinic Proc. 1995;70:1205-1214.
34. Agudelo CA, Wise CM. Crystal-associated arthritis in the elderly. Rheum Dis Clin North Am. 2000;26:527-546.
35. Fam AG. Gout in the elderly. Clinical presentation and treatment. Drugs Aging. 1998; 13:229-243.
36. Puig JG, Michan AD, Jimenez ML, et al. Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med. 1991;151:726-732.
37. Lally EV, Ho G Jr, Kaplan SR. The clinical spectrum of gouty arthritis in women. Arch Intern Med. 1986;146:2221-2225.
38. Wallace SL, Singer JZ. Therapy in gout. Rheum Dis Clin North Am. 1988;14:441-457.
39. O'Sullivan JB. Gout in a New England town. A prevalence study in Sudbury, Massachusetts. Ann Rheum Dis. 1972;31:166-169.
40. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421-426.
41. Roubenoff R, Klag MJ, Mead LA, et al. Incidence and risk factors for gout in white men. JAMA. 1991;266:3004-3007.
42. Stewart OJ, Silman AJ. Review of UK data on the rheumatic diseases - 4. Gout. Br J Rheumatol. 1990;29:485-488.
43. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. Available at: http://www.cdc.gov/nchs/data/series/sr_10/sr10200.pdf. Accessed January 6, 2003.
44. Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol. 1989;16: 427-441.
45. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11:974-979.
46. Boyer GS, Lanier AP, Templin DW. Prevalence rates of spondyloarthropathies, rheumatoid arthritis, and other rheumatic disorders in an Alaskan Inupiat Eskimo population. J Rheumatol 1988;15:678-683.
47. Cassim B, Mody GM, Deenadayalu VK, Hammond MG. Gout in black South Africans: A clinical and genetic study. Ann Rheum Dis. 1994;53:759-762.
48. Chang HY, Pan WH, Yeh WT, Tsai KS Hyperuricemia and gout in Taiwan: Results from the Nutritional and Health Survey in Taiwan (1993-96). J Rheumatol. 2001;28: 1640-1646.
49. Chang SJ, Ko YC, Wang TN, et al. High prevalence of gout and related risk factors in Taiwan's Aborigines. J Rheumatol. 1997;24:1364-1369.
50. Chen S, Du H, Wang Y, Xu L. The epidemiology study of hyperuricemia and gout in a community population in Huangpu District in Shanghai. Chin Med J (Engl). 1998; 111: 228-230.
51. Chou CT, Pei L, Chang DM, et al. Prevalence of rheumatic diseases in Taiwan: A population study of urban, suburban, rural differences. J Rheumatol. 1994;21:302-306.
52. Chou CT, Lai JS. The epidemiology of hyperuricemia and gout in Taiwan aborigines. Br J Rheumatol. 1998;37:258-262.
53. Darmawan J, Valkenburg HA, Muirden KD, Wigley RD. The epidemiology of gout and hyperuricemia in a rural population of Java. J Rheumatol. 1992;19:1595-1599.
54. Gardner MJ, Power C, Barker DJ, Padday R. The prevalence of gout in three English towns. Int J Epidemiol. 1982;11:71-75.
55. Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol. 1995;48:1153-1158.
56. Isomaki HA. Prevalence and social impact of rheumatic diseases in Finland. J Rheumatol Suppl. 1983;10:29-33.
57. Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis. 1997;56:22-26.
58. Lutalo SK. Chronic inflammatory rheumatic diseases in black Zimbabweans. Ann Rheum Dis. 1985;44:121-125.
59. Mijiyawa M. Gout in patients attending the rheumatology unit of Lome Hospital. Br J Rheumatol. 1995;34:843-846.
60. Mody GM, Naidoo PD. Gout in South African blacks. Ann Rheum Dis. 1984;43:394-397.
61. Stein CM, Svoren B, Davis P, Blankenberg B. A prospective analysis of patients with rheumatic diseases attending referral hospitals in Harare, Zimbabwe. J Rheumatol. 1991;18:1841-1844.
62. Stein M, Davis P Rheumatic disorders in Zimbabwe: A prospective analysis of patients attending a rheumatic diseases clinic. Ann Rheum Dis. 1990;49:400-402.
63. Healey LA, Skeith MD, Decker JL, Bayani-Sioson PS. Hyperuricemia in Filipinos: Interaction of heredity and environment. Am J Hum Genet. 1967;19:81-85.
64. Schlesinger N, Gowin KM, Baker DG, et al. Acute gouty arthritis is seasonal. J Rheumatol. 1998;25:342-344.
65. Gallerani M, Govoni M, Mucinelli M, et al. Seasonal variation in the onset of acute microcrystalline arthritis. Rheumatology. 1999;38:1003-1006.
66. Arber N, Vaturi M, Schapiro JM, et al. Effect of weather conditions on acute gouty arthritis. Scand J Rheumatol. 1994;23:22-24.
67. McLeod J. Gout and fibrositis in cold weather. Med J Aust. 1972;1:943. Letter.
68. McCarty DJ. Gout without hyperuricemia. JAMA. 1994;271:302-303.
69. Park YB, Park YS, Song J, et al. Clinical manifestations of Korean female gouty patients. Clin Rheumatol. 2000;19:142-146.
70. Fleckenstein JL, Wallis WJ, Simkin PA. Uric acid excretion in women. Arthritis Rheum. 1983;26(Suppl):S11. Abstract.
71. Reginato AJ, Schumacher HR Jr. Crystal-associated arthropathies. Clin Genatr Med. 1988;4:295-322.
72. Grodzicki T, Palmer A, Bulpitt CJ, for the General Practice Hypertension Study Group. Incidence of diabetes and gout in hypertensive patients during 8 years of follow-up. J Hum Hypertens. 1997;11:583-585.
73. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27:1501-1505.
74. Mijiyawa M, Oniankitan O. Risk factors for gout in Togolese patients. Joint Bone Spine. 2000;67:441-445.
75. Hochberg MC, Thomas J, Thomas DJ, et al. Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum. 1995;38:628-632.
76. Emmerson BT. The management of gout. N Engl J Med. 1996;334:445-451.
77. Sturrock RD. Gout. Easy to misdiagnose. BMJ. 2000;320:132-133.
78. Tan N, Lertratanakul Y, Barr WG. Acute gouty arthritis. Modern approaches to an ancient disease. Postgrad Med. 1993;94:73-75, 78, 83-84.
79. Schlesinger N, Schumacher HR Jr. Gout: Can management be improved? Curr Opin Rheumatol. 2001;13:240-244.
80. Conaghan PG, Day RO. Risks and benefits of drugs used in the management and prevention of gout. Drug Saf. 1994;11:252-258.
81. Setter SM, Baker DE. Selective COX-2 inhibitors: Celecoxib, rofecoxib. In: Anderson PO, Knoben JE, Troutman WG, eds. Handbook of Clinical Drug Data. 10th ed. New York: McGraw-Hill; 2002:23-25.
82. Bellamy N, Downie WW, Buchanan WW. Observations on spontaneous improvement in patients with podagra: Implications for therapeutic trials of non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol. 1987;24:33-36.
83. Stuart RA, Gow PJ, Bellamy N, et al. A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis. N Z Med J. 1991;104:115-117.
84. Bellamy N, Gilbert JR, Brooks PM, et al. A survey of current prescribing practices of antiinflammatory and urate lowering drugs in gouty arthritis in the province of Ontario. J Rheumatol. 1988;15:1841-1847.
85. Bellamy N, Brooks PM, Emmerson BT, et al. A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis in New South Wales and Queensland. Med J Aust. 1989;151:531-537.
86. Simkin PA. Gout and hyperuricemia. Curr Opin Rheumatol. 1997;9:268-273.
87. Rozenberg S, Lang T, Laatar A, et al. Diversity of opinions on the management of gout in France. A survey of 750 rheumatologists. Rev Rhum Engl Ed. 1996;63: 255-261.
88. Pal B, Foxall M, Dysart T, et al. How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol. 2000;19:21-25.
89. Schumacher HR Jr. Crystal deposition disease. Curr Opin Rheumatol. 1997;9:251-252.
90. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin. 1991;12:423-429.
91. Lomen PL, Turner LF, Lamborn KR, et al. Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. Am J Med. 1986;80:134-139.
92. Butler RC, Goddard DH, Higgens CS, et al. Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. Br J Clin Pharmacol. 1985;20:511-513.
93. Eberl R, Dunky A. Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study. Arzneimittelforschung. 1983;33:641-643.
94. Karachalios GN. Treatment of acute gouty arthritis with piroxicam. Clin Exp Rheumatol. 1985;3:63-65.
95. Cobra CJ, Cobra JF, Cobra Neto C. Use of piroxicam in the treatment of acute gout. Eur J Rheumatol Inflamm. 1983;6:126-133.
96. Shrestha M, Morgan DL, Moreden JM, et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med. 1995;26:682-686.
97. Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002;324:1488-1492.
98. Segasothy M, Chin GL, Sia KK, et al. Chronic nephrotoxicity of anti-inflammatory drugs used in the treatment of arthritis. Br J Rheumatol. 1995;34:162-165.
99. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol. 1998;93:2037-2046.
100. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum. 1998;28:48-59.
101. Moreland LW, Ball GV. Colchicine and gout. Arthritis Rheum. 1991;34:782-786.
102. Lange U, Schumann C, Schmidt KL. Current aspects of colchicine therapy - classical indications and new therapeutic uses. Eur J Med Res. 2001;6:150-160.
103. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med. 1987;17:301-304.
104. Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316:1562-1568.
105. Evans TI, Wheeler MT, Small RE, et al. A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed. J Rheumatol. 1996;23: 143-148.
106. Maldonado MA, Salzman A, Varga J. Intravenous colchicine use in crystal-induced arthropathies: A retrospective analysis of hospitalized patients. Clin Exp Rheumatol. 1997;15:487-492.
107. Roberts WN, Liang MH, Stern SH. Colchicine in acute gout. Reassessment of risks and benefits. JAMA. 1987;257:1920-1922.
108. Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol. 1993;20:111-113.
109. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: A clinical trial and review of the literature. Semin Arthritis Rheum. 1990;19:329-336.
110. Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: An effective alternative to nonsteroidal anti-inflammatory drugs. Rev Rhum Engl Ed. 1996;63:248-254.
111. Gray RG, Gottlieb NL. Intra-articular corticosteroids. An updated assessment. Clin Orthop. 1983;177:235-263.
112. Ritter J, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: Effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol. 1994;21:696-699.
113. Taylor CT, Brooks NC, Kelley KW. Corticotropin for acute management of gout. Ann Pharmacother. 2001;35:365-368.
114. Schlesinger N, Baker DG, Schumacher HR Jr. How well have diagnostic tests and therapies for gout been evaluated? Curr Opin Rheumatol. 1999;11:441-445.
115. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum. 1988;31:803-805.
116. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol. 1994; 21:1325-1327.
117. Schumacher HR. Crystal-induced arthritis: An overview. Am J Med. 1996;100(Suppl 2A):46S-52S.
118. Rosenthal AK, Ryan LM. Treatment of refractory crystal-associated arthritis. Rheum Dis Clin North Am. 1995;21:151-161.
119. Ferraz MB. An evidence based appraisal of the management of nontophaceous interval gout. J Rheumatol. 1995;22:1618-1619.
120. Fam AG. Should patients with interval gout be treated with urate lowering drugs? J Rheumatol. 1995;22:1621-1623.
121. Ferraz MB, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol. 1995;22:908-914.
122. Fries JF. Advances in management of rheumatic disease. 1965 to 1985. Arch Intern Med. 1989;149:1002-1011.
123. Ho G Jr, DeNuccio M. Gout and pseudogout in hospitalized patients. Arch Intern Med. 1993;153:2787-2790.
124. Solomon DH, Bates DW, Panush RS, Katz JN. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: A critical review of the literature and proposed methodologic standards. Ann Intern Med. 1997;127:52-60.
125. The older population in the United States: March 2000, detailed tables (PPL-147). US Census Bureau, Population Division, Racial Statistics Branch Web site. Available at: hnp://www.census.gov/population/www/socdemo/age/ppl-147.html. Accessed January 6, 2003.